Alnylam Shares Drop After AstraZeneca Posts Negative Trial Data
AstraZeneca released full data from its failed Phase 3 trial for Wainua, an RNA-targeting therapy developed with Ionis Pharma to treat ATTR-CM, a rare heart condition. The negative results led to a decline in shares of Alnylam Pharmaceuticals, which is also developing similar therapies and faces increased competitive pressure. The failure highlights the risks associated with RNA-based drug development for complex diseases like cardiomyopathy. Investors are now reassessing confidence in companies working on related treatments, particularly those relying heavily on this therapeutic approach.
